文献速递皮肤肿瘤

基线实验室参数预测伊匹木单抗治疗黑色素瘤临床结局的单中心分析

Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-11-22

该单中心回顾性分析纳入52例接受伊匹木单抗治疗的皮肤黑色素瘤患者,评估基线实验室参数与疗效及生存的关系。多因素分析显示抗PD-1预处理是客观缓解率的显著预测因素,低LDH和超过2个伊匹木单抗周期是PFS的独立预测因素,低S100B及伊匹木单抗前后抗PD-1治疗是MSS的独立预测因素。基线白细胞、淋巴细胞、嗜酸性粒细胞、血小板、NLR、PLR、ELR及维生素D水平与ORR、PFS和MSS无显著关联,粪钙卫蛋白不预测免疫性结肠炎。

要点

  • 低血清LDH是伊匹木单抗治疗黑色素瘤PFS改善的独立预测因素
  • 低血清S100B是黑色素瘤特异性生存改善的独立预测因素
  • 基线粪钙卫蛋白不预测伊匹木单抗诱导的自身免疫性结肠炎

核心结论

  • 伊匹木单抗治疗前低血清LDH是PFS改善的独立预测因素。
  • 低血清S100B是MSS改善的独立预测因素。
  • 伊匹木单抗周期数超过2与PFS延长显著相关。

研究设计与样本

  • 单中心回顾性分析,纳入52例接受伊匹木单抗治疗的皮肤黑色素瘤患者。
  • 收集患者特征及多种实验室参数,进行单变量和多变量统计,包括逻辑回归分析和Cox比例风险回归。

主要发现

  • 基线白细胞、淋巴细胞、嗜酸性粒细胞、血小板、中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值、嗜酸性粒细胞/淋巴细胞比值及血清维生素D水平与ORR、PFS和MSS无显著关联。
  • 多因素分析确认抗PD-1预处理是伊匹木单抗治疗后ORR的显著预测因素。
  • 低LDH水平和超过2个伊匹木单抗周期是PFS延长的显著独立预测因素。
  • 低S100B水平及伊匹木单抗治疗前后接受抗PD-1治疗是MSS改善的显著独立预测因素。
  • 上述所有参数及粪钙卫蛋白均不是伊匹木单抗诱导的自身免疫相关不良事件及自身免疫性结肠炎的预测因素。

关键数值与推荐

  • 总体缓解率(ORR)在晚期黑色素瘤中接受伊匹木单抗治疗仅约10%。
  • 低LDH水平(具体阈值未报告)为PFS延长的独立预测因素。
  • 低S100B水平(具体阈值未报告)为MSS改善的独立预测因素。
  • 伊匹木单抗周期数超过2与PFS延长显著相关。

临床怎么用

  • 治疗前可检测血清LDH和S100B水平,低LDH提示PFS可能获益,低S100B提示MSS可能获益。
  • 伊匹木单抗治疗周期数超过2与PFS延长相关,但需结合临床情况决定治疗周期。
  • 基线粪钙卫蛋白不宜用于预测伊匹木单抗诱导的自身免疫性结肠炎。

局限性

  • 单中心回顾性分析,样本量较小(n=52),结论需更大样本验证。
  • 未报告LDH和S100B的具体阈值,无法直接用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overall response rates (ORRs) for ipilimumab in advanced melanoma are only about 10%. Hence, it is important to explore biomarkers predicting ipilimumab responders. OBJECTIVE: We aimed to explore biomarkers to predict therapy outcome in melanoma patients who have undergone standard ipilimumab therapy in a real-world setting. METHODS: Databases of cutaneous melanoma patients (n = 52) who had received ipilimumab were reviewed and data collected on patient characteristics and diverse laboratory parameters. We performed univariate and multivariate statistics including logistic regression analysis and Cox proportional-hazards regression. RESULTS: Baseline leucocytes, lymphocytes, eosinophils, thrombocytes, neutrophil/lymphocyte ratio, thrombocytes/lymphocyte ratio, eosinophil/lymphocyte ratio and serum vitamin D levels were not significantly associated with ORR, progression-free survival (PFS) and melanoma-specific survival (MSS). Multivariate analysis confirmed anti-PD-1 pretreatment as significant predictor for ORR following ipilimumab therapy. Low-LDH levels and more than two ipilimumab cycles turned out to be significant independent predictors for prolonged PFS. Low-S100B levels and anti-PD-1 treatment before or after ipilimumab were significant independent predictors for improved MSS. All aforementioned parameters and faecal calprotectin did not turn out to be predictors for ipilimumab-induced autoimmune-related adverse events and autoimmune colitis, respectively. CONCLUSIONS: Low serum LDH before ipilimumab treatment is an independent predictor for improved PFS. Furthermore, low serum S100B is an independent predictor for MSS. The number of ipilimumab cycles (>2) is significantly associated with prolonged PFS. Pretreatment calprotectin does not predict the occurrence of autoimmune colitis under ipilimumab therapy.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gambichler T, Brown V, Steuke AK, et al. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis. J Eur Acad Dermatol Venereol. 2017. PMID: 29024038. doi:10.1111/jdv.14629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。